Bio Green Med Solution, Inc. — fact timeline

Bio Green Med Solution, Inc. entered into Business Combination Agreement with Future NRG Sdn. Bhd. and each of the shareholders of FNRG valued at The Selling Shareholders will voluntarily exchange all of their ordinary shares in FNRG for shares o (effective 2026-06-04).

“On June 4, 2026, Bio Green Med Solution, Inc., a Delaware corporation (the "Company"), Future NRG Sdn. Bhd., a Malaysia private limited company ("FNRG") and each of the shareholders of FNRG (the "Selling Shareholders"), entered into a Business Combination Agreement (the "BCA"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the BCA, the Selling Shareholders will voluntarily exchange all of their ordinary shares in FNRG for shares of common stock, par value $0.001 of the Company (the "Exchange Shares"), resulting in FNRG becoming a wholly owned subsidiary of the Company (the "Exchange").”

Bio Green Med Solution, Inc. reported fourth quarter and year ended December 31, 2025 results: net income Net loss for the three months and year ended December 31, 2025, was $0.6 million and $3.0 million.

“announcing certain financial results for the fourth quarter and year ended December 31, 2025”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5810(c)(3)(D)).

“um Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s letter further advised that for the prior 30 consecutive business days, the Preferred Stock no longer meets this requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until March 10, 2026, to regain compliance with the MVPHS requirement for its Preferred Stock. On March 12, 2026, the Company received another letter from the Staff of Nasdaq, notifying the Company that (i) the Preferred Stock has not regained com”

Bio Green Med Solution, Inc. completed a disposition involving Tethra Biosciences Inc. for $300,000, plus a further potential Milestone of $170,000 (closed 2025-10-06).

“of the Company related to Plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies (“Plogo”), for a purchase price of $300,000, plus a further potential Milestone (as defined in the Purchase Agreement) of $170,000. The Purchase Agreement contains customary representations, warranties and covenants. The”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5460(a)(2), 5810(c)(3)(D)).

“September 11, 2025, Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that its 6% Convertible Exchangeable Preferred Stock (listed on the Nasdaq Capital Market under the symbol “BGMSP”) (the “Preferred Stock”) no longer complies with the requirement under Nasdaq Listing Rule 5460(a)(2) to maintain a minimum Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s”

Bio Green Med Solution, Inc. completed an acquisition involving FITTERS Diversified Berhad for 699,158 shares of common stock, par value $0.001, of the Company (closed 2025-09-12).

“f FITTERS Diversified Berhad, a Malaysian publicly listed company (“Fitters Parent”), pursuant to a share exchange agreement”

Bio Green Med Solution, Inc. engaged SFAI Malaysia PLT as its auditor.

“On August 22, 2025, the Audit Committee approved the engagement of SFAI as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective August 23, 2025.”

Bio Green Med Solution, Inc. dismissed Bush & Associates CPA LLP as its auditor.

“ismissal of Independent Registered Public Accounting Firm On August 22, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of Cyclacel Pharmaceuticals, Inc. (the “Company”) approved the dismissal of Bush & Associates CPA LLP (“Bush”), as the Company’s independent registered public accounting firm, effective immediately.”

Bio Green Med Solution, Inc.: Filing of Amended and Restated Certificate of Designations for Series F Convertible Preferred Stock removing the Series F Ownership Limitation (effective 2025-07-28).

“On July 28, 2025, after obtaining the approval of the Board of Directors and majority stockholder of Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as disclosed in the Company’s Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on July 7, 2025 (the “Schedule 14C”), the Company filed an Amended and Restated Certificate of Designations, Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the “Restated Certificate of Designation”) with the Secretary of State of the State of Delaware.”

Bio Green Med Solution, Inc.: Filed Certificate of Amendment to implement a one-for-fifteen reverse stock split to meet Nasdaq bid price requirements (effective 2025-07-07).

“On July 2, 2025, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed an amendment to its Certificate of Incorporation (“Certificate of Amendment”) to implement a one-for-fifteen reverse stock split.”

Satis Waran Nair Krishnan was appointed as independent director at Bio Green Med Solution, Inc..

“On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.”

Inigo Angel Laurduraj was appointed as independent director at Bio Green Med Solution, Inc..

“On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.”

David Natan resigned as independent director at Bio Green Med Solution, Inc..

“on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.”

Avraham Ben-Tzvi resigned as independent director at Bio Green Med Solution, Inc..

“on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.”

David Lazar resigned as co-principal financial officer and co-principal accounting officer at Bio Green Med Solution, Inc..

“On March 31, 2025, David Lazar, the Company’s co-principal financial officer and co-principal accounting officer agreed to delay his previously announced resignation from March 31, 2025 until the date that the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), is filed with the Securities and Exchange Commission (“SEC”). On such date, Mr. Lazar’s resignation shall be automatically effective.”

Datuk Dr. Doris Wong Sing Ee was elected as Director at Bio Green Med Solution, Inc..

“Datuk Dr. Doris Wong Sing Ee was also elected to the Board of the Company as of the effective date.”

Datuk Dr. Doris Wong Sing Ee was appointed as Chief Executive Officer at Bio Green Med Solution, Inc..

“the Board appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company’s principal executive officer.”

David Lazar resigned as Interim Chief Executive Officer at Bio Green Med Solution, Inc..

“David Lazar, the Company’s interim Chief Executive Officer, interim principal financial officer, interim principal accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective February 26, 2025.”

Avraham Ben-Tzvi was appointed as Director at Bio Green Med Solution, Inc..

“The Board of Directors also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors, effective as of the signing of the Purchase Agreement and as of January 5, 2025, respectively.”

David Natan was appointed as Director at Bio Green Med Solution, Inc..

“The Board of Directors also appointed Messrs. David Natan and Avraham Ben-Tzvi as members of the Board of Directors, effective as of the signing of the Purchase Agreement and as of January 5, 2025, respectively.”

Karin Walker resigned as Director at Bio Green Med Solution, Inc..

“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”

Kenneth Ferguson resigned as Director at Bio Green Med Solution, Inc..

“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”

Brian Schwartz resigned as Director at Bio Green Med Solution, Inc..

“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”

Christopher Henney resigned as Director at Bio Green Med Solution, Inc..

“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”

Robert Spiegel resigned as Director at Bio Green Med Solution, Inc..

“Dr. Robert Spiegel, Dr. Christopher Henney, Dr. Brian Schwartz, Dr. Kenneth Ferguson and Ms. Karin Walker (together, the "Resigning Directors") resigned effective as of the signing of the Purchase Agreement.”

David E. Lazar was appointed as interim Chief Executive Officer at Bio Green Med Solution, Inc..

“the Board of Directors appointed Mr. Lazar as interim Chief Executive Officer of the Company, effective as of the signing of the Purchase Agreement.”

Spiro Rombotis resigned as Chief Executive Officer at Bio Green Med Solution, Inc..

“Mr. Spiro Rombotis resigned as Chief Executive Officer of the Company”

Dr. Christopher Henney changed role as Director at Bio Green Med Solution, Inc..

“Effective June 21, 2024, by resolution of the board of directors of the Company, Dr. Samuel L. Barker was appointed Chair of the board of directors to replace Dr. Christopher Henney, who requested to step down as Chair but will continue as a director of the Company.”

Dr. Samuel L. Barker was appointed as Chair of the board at Bio Green Med Solution, Inc..

“Effective June 21, 2024, by resolution of the board of directors of the Company, Dr. Samuel L. Barker was appointed Chair of the board of directors to replace Dr. Christopher Henney, who requested to step down as Chair but will continue as a director of the Company.”

Bio Green Med Solution, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the three months March 31, 2024, was $2.9 million (including stock-based compensation expense of $0.2 milli.

“Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.”

Bio Green Med Solution, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $8.0 million (effective 2024-04-30).

“On April 30, 2024, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 145,000 shares of the Company’s common stock”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 27, 2024, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company reported stockholders’ equity of less than $2.5 million as of December 31, 2023. The Company’s stockholders’ equity was $607,000 as of December 31, 2023. The Company must submit a plan to the Staff no later than May 10, 2024 advising of actions it has taken or will take to regain compliance with Nasdaq Listing”

Bio Green Med Solution, Inc. reported the year ended December 31, 2023 results: net income $22.6 million.

“Net loss for the three months and year ended December 31, 2023, was $5.3 million and $22.6 million”

Bio Green Med Solution, Inc. reported the three months ended December 31, 2023 results: net income $5.3 million.

“Net loss for the three months and year ended December 31, 2023, was $5.3 million”